WO2003002510A1 - Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant - Google Patents
Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant Download PDFInfo
- Publication number
- WO2003002510A1 WO2003002510A1 PCT/FR2002/002235 FR0202235W WO03002510A1 WO 2003002510 A1 WO2003002510 A1 WO 2003002510A1 FR 0202235 W FR0202235 W FR 0202235W WO 03002510 A1 WO03002510 A1 WO 03002510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorophenyl
- tetrahydronaphthalen
- hydroxyethylamino
- yloxy
- ethyl acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the subject of the present invention is a new crystalline form, hereinafter called form B, of hydrochloride of [(7S) 7 - [(2R) 2- (3-chlorophenyl) -2-hydroxyethylamino] -5,6,7, 8- tetrahydronaphthalen-2-yloxy] -ethyl acetate, its preparation and the pharmaceutical compositions containing it.
- the subject of the present invention is form B of [(7S) 7 - [(2R) 2- (3-chlorophenyl) -2-hydroxyethylamino] -5,6,7,8-tetrahydronaphthalen-2-yloxy hydrochloride ] -ethyl acetate which has in particular the following physical characteristics:
- FIG. 2 shows the X-ray powder diffraction diagram of the compound of form B (obtained with a Cu K ⁇ 1 source in a ⁇ / ⁇ configuration, rear monochromator).
- form B of SR 58611A or the compound of the invention means a product comprising at least 95% by weight and preferably at least 99% by weight of form B alongside the other polymorphs.
- the subject of the invention is form B which is essentially free from the other polymorphic forms according to current methods of analysis.
- the invention also includes a process for preparing the compound according to the invention, characterized in that a concentrated HCl solution is added to a solution of [(7S) 7- [(2R) 2- (3-chlorophenyl) - 2-hydroxyethylamino] -5,6,7,8-tetrahydronaphthalen-2-yloxy] - ethyl acetate in a solvent chosen from propan-2-ol, 2-methylpropan-2-ol and butan-2- ol at a temperature ranging from 40 to 70 ° C, the crystallization is initiated by seeding with a small amount of form B, then the solution is gradually cooled.
- a concentrated HCl solution is added to a solution of [(7S) 7- [(2R) 2- (3-chlorophenyl) - 2-hydroxyethylamino] -5,6,7,8-tetrahydronaphthalen-2-yloxy] - ethyl acetate in a solvent
- the crystallization is carried out at a temperature of 50 to 70 ° C.
- said solvent is propan-2-ol.
- the concentrated hydrochloric acid may be that of the trade generally containing 35 to
- the compound of the invention can also be prepared by a recrystallization process, characterized in that the [(7S) 7 - [(2R) 2- (3-chlorophenyl) -2-hydroxyethylamino] hydrochloride is suspended -5,6,7,8-tetrahydronaphthalen-2-yloxy] -ethyl acetate, in crude form or mixture of crystalline forms, in propan-2-ol, 2-methylpropan-2-ol or butan 2-ol at room temperature at 70 ° C. and the suspension is kept in isothermal until the crystals transform to form B.
- recrystallization is carried out by priming with a small amount of form B in order to cause the desired specific nucleation. If no primer is available, it is however possible to spontaneously obtain the transformation into form B by maintaining the other crystalline forms or the mixtures in suspension in particular in an alcohol as mentioned above for a sufficient time dependent on the temperature. , especially between room temperature and below the boiling point of alcohol.
- the product of the invention can be prepared by heating a solution of [(7S) 7 - [(2R) 2- (3-chlorophenyl) -2-hydroxyethylamino] - 5,6 hydrochloride, 7,8-tetrahydronaphthalen-2-yloxy] -ethyl acetate, in an organic solvent such as an alcohol or a ketone, at a temperature of 45 to 70 ° C, concentration of the solution by evaporation or distillation, then cooling progressive solution with stirring at a temperature of 10 to 40 ° C.
- an organic solvent such as an alcohol or a ketone
- form B is the most thermodynamically stable form at room temperature or more generally at a temperature less than or equal to 70 ° C., because the other forms A and C or their mixtures end up by transforming into form B when they are kept in solution or suspension at a certain temperature for a sufficiently long time (see examples 3 and 4), whatever the solvent.
- form B can be obtained with better productivity both for crystallization and for filtration and drying, especially when it is prepared in propane. 2-ol.
- Example 1 Preparation of Form B of SR58611 hydrochloride (SR58611A).
- the medium is primed with 2% (relative to the mass of SR58611A introduced) of SR58611A form B suspended in propan-2-ol. After 1 hour of isotherm at the seeding temperature, the suspension is cooled to 20 ° C with a linear cooling ramp of -10 ° C / h. The product is separated by filtration, washed with propan-2-ol (1 x 400 ml) and dried at 50 ° C under reduced pressure to give SR58611 hydrochloride of form B (190 g), melting point 125-130 ° vs.
- Example 3 Kinetic transformation of SR58611A polymorphic mixture in form B.
- Polymorphic SR58611 hydrochloride (4.46 g) is suspended at ambient temperature in 0.3 liters of propan-2-ol. After 70 h of isotherm, the suspension consists of SR 58611 A hydrochloride, form B,> 96%. IR and RX compliant.
- Example 4 Kinetic transformation of the SR58611A polymorphic mixture into form B.
- Polymorphic SR58611 hydrochloride (95.2 g) is suspended at 70 ° C. in 0.3 liters of propan-2-ol. After 12:30 of isotherm, the suspension consists of SR58611 hydrochloride, form B,> 98%. IR and RX compliant.
- Example 5 Industrial preparation of SR58611A form B.
- 0.49 kg of activated carbon CX and 5 l of propan-2-ol are then introduced and the temperature is brought to 80 ° C. for 30 minutes. Then the content kept at 75-78 ° C is filtered by nitrogen pressure, the tank is rinsed with 7 l of solvent and kept for another 10 minutes at 78 ° C, then the medium is concentrated under atmospheric pressure until a residual volume of 99 I. in approx. 1 h.
- the medium is cooled to 60 ° C (speed 0? 4 ° C / min.) And 0.5 kg of primer (form B) is immediately introduced with 2.5 l of propan-2-ol and maintained at 60 ° C for one hour. It is cooled to 20 ° C (speed 0.2 ° C / min), then filtered, washed with 25 l of propan-2-ol and dried under vacuum at 40 ° C then 70 ° C until a loss of weight ⁇ 0.1%. 23.04 kg of the expected product are obtained (Rt; 93.3%). IR and RX compliant.
- Example 7 Pharmaceutical composition.
- the product according to the invention can be administered for the treatment of depression at a dose ranging from 100 to 800 mg / day (calculated as a basis), in particular 300 to 600 mg / day by the oral route, depending on the severity of the disease and the patient's weight.
- Typical formulations are tablets or capsules or dragees. Examples of capsules dosed with 100 and 200 mg of active principle (base, corresponding to 109.0 and 218, respectively, Omg of hydrochloride):
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2450213A CA2450213C (fr) | 2001-06-28 | 2002-06-27 | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
MXPA03011742A MXPA03011742A (es) | 2001-06-28 | 2002-06-27 | Forma cristalina de una feniletanolamina, su preparacion y composiciones farmaceuticas que la contienen. |
BR0210661-2A BR0210661A (pt) | 2001-06-28 | 2002-06-27 | Forma cristalina de uma feniletanolamina, a respectiva preparação e composições farmacêuticas que a contêm |
HU0401229A HUP0401229A3 (en) | 2001-06-28 | 2002-06-27 | Crystal form of a phenylethanolamine hydrokloride, the preparation thereof and pharmaceutical compositions comprising the same |
NZ530140A NZ530140A (en) | 2001-06-28 | 2002-06-27 | Crystalline form of a phenylethanolamine for use as an antidepressant |
US10/480,427 US6992211B2 (en) | 2001-06-28 | 2002-06-27 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
KR1020037016946A KR100869017B1 (ko) | 2001-06-28 | 2002-06-27 | 페닐에탄올아민의 결정질 형태, 이의 제조 방법 및 이를포함하는 제약 조성물 |
JP2003508694A JP4171413B2 (ja) | 2001-06-28 | 2002-06-27 | フェニルエタノールアミンの結晶形およびそれを含む医薬組成物 |
AU2002333942A AU2002333942B2 (en) | 2001-06-28 | 2002-06-27 | Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
DE60228088T DE60228088D1 (de) | 2001-06-28 | 2002-06-27 | Kristalline form eines phenylethanolamins, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
EEP200400007A EE05380B1 (et) | 2001-06-28 | 2002-06-27 | FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid |
DK02780917T DK1404641T3 (da) | 2001-06-28 | 2002-06-27 | Krystallinsk form af en phenylethanolarmin, fremstilling herfra og farmaceutiske præparater, der indeholder den |
IL15913402A IL159134A0 (en) | 2001-06-28 | 2002-06-27 | Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
PL368055A PL206680B1 (pl) | 2001-06-28 | 2002-06-27 | Postać krystaliczna chlorowodorku [(7S)-7-[(2R)-2-(3-chlorofenylo)-2-hydroksyetyloamino]-5,6,7,8-tetrahydronaft-2-yloksy]octanu etylu, sposób jej wytwarzania i zawierający ją środek farmaceutyczny |
EP02780917A EP1404641B1 (fr) | 2001-06-28 | 2002-06-27 | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
SI200230728T SI1404641T1 (sl) | 2001-06-28 | 2002-06-27 | Kristalinična oblika feniletanolamina, njena priprava in farmacevtski pripravki, ki jo vsebujejo |
SK1593-2003A SK287355B6 (sk) | 2001-06-28 | 2002-06-27 | Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú |
IL159134A IL159134A (en) | 2001-06-28 | 2003-11-30 | Crystalline form of a phenylethanolamine, the |
NO20035839A NO331169B1 (no) | 2001-06-28 | 2003-12-29 | Krystallinsk form av et fenyletanolamin, fremstilling derav og farmasoytisk preparat og legemiddel omfattende den samme |
HK04106301.7A HK1063621A1 (en) | 2001-06-28 | 2004-08-23 | Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/08562 | 2001-06-28 | ||
FR0108562A FR2826651B1 (fr) | 2001-06-28 | 2001-06-28 | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002510A1 true WO2003002510A1 (fr) | 2003-01-09 |
Family
ID=8864888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/002235 WO2003002510A1 (fr) | 2001-06-28 | 2002-06-27 | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
Country Status (30)
Country | Link |
---|---|
US (1) | US6992211B2 (fr) |
EP (1) | EP1404641B1 (fr) |
JP (2) | JP4171413B2 (fr) |
KR (1) | KR100869017B1 (fr) |
CN (1) | CN1269797C (fr) |
AR (1) | AR034648A1 (fr) |
AT (1) | ATE403642T1 (fr) |
AU (1) | AU2002333942B2 (fr) |
BR (1) | BR0210661A (fr) |
CA (1) | CA2450213C (fr) |
CY (1) | CY1110099T1 (fr) |
CZ (1) | CZ301450B6 (fr) |
DE (1) | DE60228088D1 (fr) |
DK (1) | DK1404641T3 (fr) |
EE (1) | EE05380B1 (fr) |
ES (1) | ES2307798T3 (fr) |
FR (1) | FR2826651B1 (fr) |
HK (1) | HK1063621A1 (fr) |
HU (1) | HUP0401229A3 (fr) |
IL (2) | IL159134A0 (fr) |
MX (1) | MXPA03011742A (fr) |
NO (1) | NO331169B1 (fr) |
NZ (1) | NZ530140A (fr) |
PL (1) | PL206680B1 (fr) |
PT (1) | PT1404641E (fr) |
SI (1) | SI1404641T1 (fr) |
SK (1) | SK287355B6 (fr) |
TW (1) | TWI286129B (fr) |
WO (1) | WO2003002510A1 (fr) |
ZA (1) | ZA200309512B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005631A1 (fr) * | 2004-07-09 | 2006-01-19 | Sanofi-Aventis | Utilisation de phenylethanolaminotetralines pour preparer des medicaments anxiolytiques |
US11898201B2 (en) | 2015-12-30 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Split-cycle and tape amplification |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826651B1 (fr) * | 2001-06-28 | 2005-09-02 | Sanofi Synthelabo | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
FR2890862B1 (fr) * | 2005-09-19 | 2008-01-25 | Sanofi Aventis Sa | Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303546A2 (fr) * | 1987-08-12 | 1989-02-15 | Sanofi | Procédé pour la O-alkylation de N-(hydroxy)aralkylphényléthanolamines |
EP0489640A1 (fr) * | 1990-12-04 | 1992-06-10 | Sanofi | Utilisation de phényléthanolaminotétralines pour la préparation de médicaments antidépressifs et anti-stress |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5235103A (en) * | 1987-08-12 | 1993-08-10 | Sanofi | Process for the preparation of phenylethanolaminotetralins |
US5198586A (en) * | 1987-08-12 | 1993-03-30 | Sanofi | Process for the preparation of phenylethanolaminotetralins |
US5202466A (en) * | 1988-06-14 | 1993-04-13 | Sanofi | 2-amino-7-hydroxytetraline ethers |
FR2648042B1 (fr) * | 1989-06-13 | 1994-06-10 | Midy Spa | Utilisation de phenylethanolaminotetralines pour la preparation de medicaments pour le traitement des affections oculaires |
FR2643076B1 (fr) * | 1989-02-14 | 1991-06-21 | Midy Spa | Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline |
US5312961A (en) * | 1989-02-14 | 1994-05-17 | Elf Sanofi | 2-amino-7-hydroxytetralin carboxylalkyl ethers |
FR2826651B1 (fr) * | 2001-06-28 | 2005-09-02 | Sanofi Synthelabo | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant |
-
2001
- 2001-06-28 FR FR0108562A patent/FR2826651B1/fr not_active Expired - Fee Related
-
2002
- 2002-06-27 MX MXPA03011742A patent/MXPA03011742A/es active IP Right Grant
- 2002-06-27 NZ NZ530140A patent/NZ530140A/en not_active IP Right Cessation
- 2002-06-27 JP JP2003508694A patent/JP4171413B2/ja not_active Expired - Fee Related
- 2002-06-27 PL PL368055A patent/PL206680B1/pl not_active IP Right Cessation
- 2002-06-27 DK DK02780917T patent/DK1404641T3/da active
- 2002-06-27 US US10/480,427 patent/US6992211B2/en not_active Expired - Fee Related
- 2002-06-27 PT PT02780917T patent/PT1404641E/pt unknown
- 2002-06-27 ES ES02780917T patent/ES2307798T3/es not_active Expired - Lifetime
- 2002-06-27 EP EP02780917A patent/EP1404641B1/fr not_active Expired - Lifetime
- 2002-06-27 KR KR1020037016946A patent/KR100869017B1/ko not_active IP Right Cessation
- 2002-06-27 SI SI200230728T patent/SI1404641T1/sl unknown
- 2002-06-27 IL IL15913402A patent/IL159134A0/xx unknown
- 2002-06-27 HU HU0401229A patent/HUP0401229A3/hu unknown
- 2002-06-27 EE EEP200400007A patent/EE05380B1/xx not_active IP Right Cessation
- 2002-06-27 AU AU2002333942A patent/AU2002333942B2/en not_active Ceased
- 2002-06-27 DE DE60228088T patent/DE60228088D1/de not_active Expired - Lifetime
- 2002-06-27 BR BR0210661-2A patent/BR0210661A/pt not_active Application Discontinuation
- 2002-06-27 CZ CZ20033531A patent/CZ301450B6/cs not_active IP Right Cessation
- 2002-06-27 CA CA2450213A patent/CA2450213C/fr not_active Expired - Fee Related
- 2002-06-27 SK SK1593-2003A patent/SK287355B6/sk not_active IP Right Cessation
- 2002-06-27 WO PCT/FR2002/002235 patent/WO2003002510A1/fr active IP Right Grant
- 2002-06-27 AR ARP020102421A patent/AR034648A1/es active IP Right Grant
- 2002-06-27 CN CNB028130952A patent/CN1269797C/zh not_active Expired - Fee Related
- 2002-06-27 AT AT02780917T patent/ATE403642T1/de active
- 2002-06-27 TW TW091114166A patent/TWI286129B/zh not_active IP Right Cessation
-
2003
- 2003-11-30 IL IL159134A patent/IL159134A/en not_active IP Right Cessation
- 2003-12-08 ZA ZA200309512A patent/ZA200309512B/xx unknown
- 2003-12-29 NO NO20035839A patent/NO331169B1/no not_active IP Right Cessation
-
2004
- 2004-08-23 HK HK04106301.7A patent/HK1063621A1/xx not_active IP Right Cessation
-
2008
- 2008-07-08 JP JP2008178049A patent/JP4799592B2/ja not_active Expired - Fee Related
- 2008-09-24 CY CY20081101044T patent/CY1110099T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303546A2 (fr) * | 1987-08-12 | 1989-02-15 | Sanofi | Procédé pour la O-alkylation de N-(hydroxy)aralkylphényléthanolamines |
EP0489640A1 (fr) * | 1990-12-04 | 1992-06-10 | Sanofi | Utilisation de phényléthanolaminotétralines pour la préparation de médicaments antidépressifs et anti-stress |
Non-Patent Citations (1)
Title |
---|
CECCHI, R. ET AL., EUR. J. MED. CHEM., vol. 29, 1994, pages 259 - 267, XP008001333 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005631A1 (fr) * | 2004-07-09 | 2006-01-19 | Sanofi-Aventis | Utilisation de phenylethanolaminotetralines pour preparer des medicaments anxiolytiques |
EP1623705A1 (fr) * | 2004-07-09 | 2006-02-08 | Sanofi-Aventis | Utilization de phényléthanolaminotétralines pour la préparation de médicaments anxiolytiques |
US11898201B2 (en) | 2015-12-30 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Split-cycle and tape amplification |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1011664A6 (fr) | Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant. | |
FR2832146A1 (fr) | Base libre de tamsulosine racemique et ses procedes de preparation | |
US6809221B2 (en) | Process for preparing (+)-cis-sertraline | |
CH641181A5 (fr) | Indolo-quinolizidines, procede pour leur preparation et compositions therapeutiques les contenant. | |
EP1404641B1 (fr) | Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant | |
US20100069450A1 (en) | Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one | |
EP1102747B1 (fr) | Formes cristallines du osanetant | |
EP0703915B1 (fr) | Xamoneline tartrate | |
AU2003209603A1 (en) | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization | |
AU764844B2 (en) | Process for manufacture of L-DOPA ethyl ester | |
CH629821A5 (fr) | Derives semi-synthetiques de l'oleandomycine et leur procede de preparation. | |
WO2014037563A1 (fr) | Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables | |
JPH0341459B2 (fr) | ||
JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
FR2611716A1 (fr) | Derives de diisobutylxanthine substituee en position 7 utiles comme bronchodilatateurs, procede pour leur preparation et composition pharmaceutique les contenant | |
EP1070083A1 (fr) | Formes cristallines du 1s-[1alpha(2s*,3r*),9alpha]-6,10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isoquinolyl)carbonyl]- amino]octahydro-6h-piridazino[1,2-a][1,2]diazepine-1-carboxamide | |
BE898221A (fr) | Dérivés d'azepino (1,2-a) pyrimidine bronchodilatateurs, leurs sels d'addition d'acides et compositions pharmaceutiques qui les contiennent. | |
CH642067A5 (fr) | Sels phosphates de la 1- et de la d,1-glaucine, leur utilisation dans des compositions pharmaceutiques et procede pour leur preparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 159134 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002780917 Country of ref document: EP Ref document number: 2003/09512 Country of ref document: ZA Ref document number: 02130/DELNP/2003 Country of ref document: IN Ref document number: 200309512 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2450213 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002333942 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 530140 Country of ref document: NZ Ref document number: 2003508694 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/011742 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15932003 Country of ref document: SK Ref document number: PV2003-3531 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037016946 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028130952 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002780917 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-3531 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10480427 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 530140 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 530140 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002780917 Country of ref document: EP |